Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study

Fleischhack, Gudrun; Massimino, Maura; Warmuth‐Metz, Monika; Khuhlaeva, E.; Janßen, Gisela; Graf, Norbert; Rutkowski, Stefan; Beilken, Andreas; Schmid, Irene; Biassoni, Veronica; Gorelishev, Sergey; Kramm, Christof M.; Reinhard, Harald; Schlegel, Paul‐Gerhardt; Kortmann, Rolf‐Dieter; Reuter, Dirk; Bach, F.; Iznaga-Escobar, Normando; Bode, Udo

doi:10.1007/s11060-019-03140-z

Cited by 36 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment of brainstem gliomas includes steroids, surgery, RT, and chemotherapy [11][12][13][14] . Chemotherapy has limited effect in brainstem gliomas [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] . Temozolomide and RT combination has been standard approach in treatment of brainstem gliomas [11][12][13][14][15][16][18][19][20][21]27,28 .…”

Section: Discussionmentioning

confidence: 99%

“…Nimotuzumab (which targets epidermal growth factor receptor, EGFR) is also used in children with brainstem glioma and reported to have modest benefits on survival time 11,17,25 . The protocol involving antivascular endothelial growth factor agents: bevacizumab with irinotecan and temozolomide was shown to be feasible and tolerable in pediatric brainstem gliomas (Table 2).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric Brainstem Glioblastoma: A Systematic Review About Treatment Strategies

Oktay¹,

Güzel²,

Kupeli³

et al. 2021

jocass

View full text Add to dashboard Cite

Brainstem tumors are rare pathologies, brainstem glioblastoma is even rarer. We report three pediatric patients who underwent subtotal tumor resection for brainstem tumors diagnosed as brainstem glioblastoma. The clinical courses and treatment procedures were discussed alongside a comprehensive literature review. Treatment of brainstem high-grade gliomas includes steroids, surgery, radiotherapy, and chemotherapy. However, none of these treatment modalities effectively prolongs survival time. According to literature, the median overall survival of these patients are approximately between 9 to 12 months. Glioblastoma has a poor prognosis in pediatric patients with high-grade brainstem gliomas. Radiotherapy is associated with a decreased risk of mortality at 9 months but not long-term.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Pediatric Brainstem Glioblastoma: A Systematic Review About Treatment Strategies

Oktay¹,

Güzel²,

Kupeli³

et al. 2021

jocass

View full text Add to dashboard Cite

show abstract

“…The combination was well tolerated [ 108 ]. In 2019, a multinational phase III trial evaluated the safety and efficacy of nimotuzumab in combination with RT in newly diagnosed DMGs [ 109 ]. This study concluded that concomitant treatment with RT and nimotuzumab was feasible in an outpatient setting, but the progression-free survival and overall survival were not superior compared to the results achieved with RT and intensive chemotherapy in a hospitalized setting [ 109 ].…”

Section: Dna Repair As a Therapeutic Target To Radio-sensitize Dmgmentioning

confidence: 99%

Radio-Resistance and DNA Repair in Pediatric Diffuse Midline Gliomas

Pedersen

Schmiegelow

Hamerlik

2020

Cancers

View full text Add to dashboard Cite

Malignant gliomas (MG) are among the most prevalent and lethal primary intrinsic brain tumors. Although radiotherapy (RT) is the most effective nonsurgical therapy, recurrence is universal. Dysregulated DNA damage response pathway (DDR) signaling, rampant genomic instability, and radio-resistance are among the hallmarks of MGs, with current therapies only offering palliation. A subgroup of pediatric high-grade gliomas (pHGG) is characterized by H3K27M mutation, which drives global loss of di- and trimethylation of histone H3K27. Here, we review the most recent literature and discuss the key studies dissecting the molecular biology of H3K27M-mutated gliomas in children. We speculate that the aberrant activation and/or deactivation of some of the key components of DDR may be synthetically lethal to H3K27M mutation and thus can open novel avenues for effective therapeutic interventions for patients suffering from this deadly disease.

show abstract

“…Nimotuzumab is a monoclonal antibody of human EGFR that has been approved in several countries for glioma, head and neck cancer, and esophageal cancer. Nimotuzumab alone and with conventional agents are now under evaluation in various clinical trials, and it has shown potential efficacy in various clinical trials, including nasopharyngeal carcinoma [ 154 ], esophageal cancer [ 155 ], and glioma [ 156 ].…”

Section: Egfr Inhibitors and Their Efficacy In Cholangiocarcinomamentioning

confidence: 99%

ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications

Jin

2020

JCM

View full text Add to dashboard Cite

The erythroblastic leukemia viral oncogene homolog (ErBb) family consists of the receptor tyrosine kinases (RTK) epidermal growth factor receptor (EGFR; also called ERBB1), ERBB2, ERBB3, and ERBB4. This family is closely associated with the progression of cholangiocarcinoma (CC) through the regulation of cellular networks, which are enhanced during tumorigenesis, metastasis, and chemoresistance. Additionally, the constitutive activation of cellular signaling by the overexpression and somatic mutation-mediated alterations conferred by the ErBb family on cholangiocarcinoma and other cancers enhances tumor aggressiveness and chemoresistance by contributing to the tumor microenvironment. This review summarizes the recent findings on the molecular functions of the ErBb family and their mutations during the progression of cholangiocarcinoma. It also discusses the developments and applications of various devising strategies for targeting the ErBb family through different inhibitors in various stages of clinical trials, which are essential for improving targeted clinical therapies.

show abstract

Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study

Cited by 36 publications

References 29 publications

Pediatric Brainstem Glioblastoma: A Systematic Review About Treatment Strategies

Pediatric Brainstem Glioblastoma: A Systematic Review About Treatment Strategies

Radio-Resistance and DNA Repair in Pediatric Diffuse Midline Gliomas

ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications

Contact Info

Product

Resources

About